- ＜Management Team＞
President, CEO, Chairman of the board and co-founder
Haru is the exuberant entrepreneur as well as the dynamic investor whose leadership and strategic vision drives Modalis toward success from his co-foundation in 2016. He brings more than 25 years of biotech industry leadership experience, most recently serving 8 years as president and CEO of REGiMMUNE Corporation, a company he founded to leverage the power of regulatory T cells to manage difficult-to-treat immune conditions such as GVHD (now in clinical trials). Before that he took a leading role in business development at Y’s Therapeutics Inc. that aspired for a novel biotherapeutics using antibody technology. As a scientist, Haru played a pioneering role in the research and development of thrombopoietin (aka TPO or MGDF) at KIRIN (merged into Kyowa-Kirin Co ., Ltd.(TSE:4151)). He acquired extensive business and consulting experiences at Booz Allen Hamilton Inc. (merged into Strategy & of PwC) where he engaged in numerous projects across various industry sectors.
Tetsuya Yamagata, MD, Ph.D
SVP, Chief Technology Officer
Tetsuya leads research at Modalis to transform CRISPR technology into innovative medicine. He is an accomplished scientist who has an extensive biomedical expertise in academic, clinic and bioindustry settings. He joined Modalis in 2016 from GlaxoSmithKline plc (GSK) where he had a leadership role in developing medicine against immune-mediated disorders. Prior to GSK, he led a high-throughput biology team in the target discovery technology platform at Tempero Pharmaceuticals(later acquired by GSK). Prior to Tempero, he was an Associate Professor in Medicine at Dokkyo Medical University in Japan. He received his MD and PhD from the University of Tokyo. He completed his internship and fellowship in hematology and oncology at Tokyo University Hospital. He did his post-doctoral research at the University of Tokyo and was an Instructor in Medicine at Harvard Medical School.
Naoki Kobayashi, MBA
VP, Chief Financial Officer
Naoki has been a financial professional for the past 30 years. He started his career at Daikyo Incorporated, a real estate company, and then joined the Deloitte group where he provided consulting for biotech startups. He then joined a biotech company where he engaged as CFO to lead the company through its acquisition by a pharma company. He also led a Japanese IT company, Hatena Co.,Ltd (TSE:3930), to its successful IPO as CFO. Prior to joining Modalis, he served as CFO at Oncolys BioPharma Inc. (TSE:4588).
He received an MBA from Hitotsubashi University in Tokyo Japan
- ＜Board of Directors＞
Osamu Nureki, Ph.D
Scientific founder, Board Member
Dr.Nureki is a world-renown structural biologist who has published numerous articles on prestigious scientific journals in the CRISPR field (e.g. Cell, 2014, 2015 & 2016). He has a long-lasting collaboration relationship with Dr. Feng Zhang at Broad Institute, one of the key discoverers of CRISPR technology. He and Dr. Zhang co-publish many scientific papers and co-file key critical patents on CRISPR and gene editing technologies. He received his PhD from University of Tokyo. He is currently a professor at Department of Biophysics and Biochemistry, Graduate School of Science in the University of Tokyo.
Hideki is a partner at Medical Patent Research, where he assists early and established biotech companies to develop and prosecute intellectual property strategies. He co-founded Retina Institute Japan which merged into Healios K.K.(TSE:4593), where he served as a board member. He has held operational roles that include the development of intellectual property strategies at Fujisawa Pharmaceutical Co., Ltd.
, which merged into Astellas Pharma Inc.(TSE:4503),, and the foundation for biomedical research and innovation.
Joseph S McCracken, DVM
Dr. McCracken held the position of Vice President, Business Development at Genentech, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer (merged into Sanofi). He was General Manager, Roche Pharma Japan & Asia Regional Head, and Roche Partnering. He was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma, where he was responsible for Roche Pharma's global in-licensing and out-licensing activities. He currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives and serves on the Boards of Alkahest, Kindred Biosciences, REGiMMUNE Corporation, and Savara Pharmaceuticals.
He holds a BS in Microbiology, a MS in Pharmacology and a DVM from The Ohio State University.
Board Member (audit committee member)
Miyuki engaged in research and development of new bioproducts for more than 40 years in Chugai Pharmaceutical Co., Ltd (TSE:4519) particularly development of the first biopharmaceutical product in Japan. She led a study group of disease-related gene searches by the genome analysis and has experiences in drug discovery and development based on cell and genome biology.
Teruhisa Tajima, CPA
Board Member (Audit committee)
Director, representing Tajima CPA office
Teruhisa has over 20 years of experience in accounting and corporate finance. He worked at ChuoAoyama Audit Corporation(a member firm of PwC) as a consultant for start-ups, supporting their growth and successful exit via M&A or IPOs. He has also served as external auditor for Longreach Group and CYBIRD Holdings Co., Ltd. and has supported many biotech start-ups, including Quantum Biosystems Inc.
Toshio Furuta, Attorney at law
Board Member (Audit committee)
Attorney in private practice at Clair Law Firm
Toshio is an experienced attorney with 30 years of practice. He brings broad expertise in corporate and commercial law to Modalis. His practice focuses on startup companies, not only in lifescience/biotech but in other technology sectors. He currently serves as a board member or external auditor at CanBas Co.,Ltd.(TSE:4575), Netyear Group Corporation (TSE:3622), and Transaction (TSE:7818).